New York Eye and Ear Infirmary
Adjust: Text Size Make Font Smaller Make Font Larger Print this Page: Normal Print Friendly Large Print Friendly Accessibility Info

A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys XEN45 Glaucoma Implant in Subjects with Refractory Glaucoma

This study is currently recruiting participants.

Purpose: This is a prospective, Multicenter Clinical Trial Designed to evaluate the safety and IOP lowering performance of the AqueSys XEN45 Glaucoma Implant in refractory glaucoma patients where previous filtering or cilioablative procedures have failed, or byexperience is known to not provide satisfactory results, or IOP has been unresponsive to maximally tolerated medication.

Eligibility:

  • Age 45 Years and older with a diagnosis of Refractory Glaucoma
  • Maximally-tolerated medicated IOP at two preoperative visits of greater than or equal to 20 mmHg and less than or equal to 35 mmHg
  • Detectable glaucomatous field defect with mean deviation score of -3 dB or worse
  • Shaffer Angle Grade greater than or equal to 3
  • Area of free, healthy and mobile conjunctiva in the targeted quadrant

Contact Information

Dr. Joseph Panarelli, Glaucoma Specialist

Priya Mehta, Clinical Research Coordinator at 212-979-4672 or pmehta@nyee.edu

 

Home > Current Research > Clinical Trials in Ophthalmology > A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys XEN45 Glaucoma Implant in Subjects with Refractory Glaucoma